This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zoetis Inc. came into existence following Pfizer’s decision to spin off its animal health business. he company is a leader in the discovery, development, manufacture and commercialization of animal health medicines, vaccines and diagnostic products with a focus on both livestock and companion animals. Zoetis has a diversified business, which caters to eight core species — cattle, swine, poultry, fish and sheep (collectively, livestock) and dogs, cats and horses (collectively, companion animals).
4 GARP Stocks to Scoop Up for Maximum Returns
by Zacks Equity Research
If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.
Is Zoetis (ZTS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (ZTS) Outperforming Other Medical Stocks This Year?
5 Drug/Biotech Stocks Likely to Surpass on Earnings in Q3
by Zacks Equity Research
Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the third quarter.
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
3 Reasons Why Zoetis (ZTS) Is a Great Growth Stock
by Zacks Equity Research
Zoetis (ZTS) could produce exceptional returns because of its solid growth attributes.
Is Zoetis (ZTS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (ZTS) Outperforming Other Medical Stocks This Year?
Zoetis (ZTS) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Can Zoetis (ZTS) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
Zoetis Appoints Kristin Peck as New CEO, Alaix to Retire
by Zacks Equity Research
Zoetis (ZTS) names executive vice president Kristin Peck as the new CEO, effective Jan 1, 2020.
IDEXX's Kidney Function Test Included in IRIS Staging Views
by Zacks Equity Research
IDEXX (IDXX) is upbeat about the inclusion and approval of the SDMA-based renal care staging guidelines.
Is Zoetis (ZTS) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
Zoetis (ZTS) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Is Zoetis (ZTS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (ZTS) Outperforming Other Medical Stocks This Year?
Zoetis (ZTS) Receives EC Approval for Simparica Trio in Dogs
by Zacks Equity Research
Zoetis' (ZTS) leading animal health portfolio gets a boost with the approval of Simparica Trio.
ASRT vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
ASRT vs. ZTS: Which Stock Is the Better Value Option?
Buy These 7 Small Drugmakers to Boost Your Portfolio's Health
by Kinjel Shah
Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity have kept small drugmakers afloat in a competitive market.
Is Zoetis (ZTS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (ZTS) Outperforming Other Medical Stocks This Year?
Small Drug Stock Outlook: Innovation Holds the Key to Growth
by Kinjel Shah
Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity have kept small drugmakers afloat in a competitive market.
Why Is Zoetis (ZTS) Up 5.5% Since Last Earnings Report?
by Zacks Equity Research
Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FTCS
ASRT vs. ZTS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ASRT vs. ZTS: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights: Procter & Gamble, T-Mobile, Zoetis, Autodesk and FedEx
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Procter & Gamble, T-Mobile, Zoetis, Autodesk and FedEx
Top Stock Reports for Procter & Gamble, T-Mobile & Zoetis
by Mark Vickery
Today's Research Daily features updated research reports on 16 major stocks, including Procter & Gamble (PG), T-Mobile (TMUS) and Zoetis (ZTS).
Is Zoetis (ZTS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (ZTS) Outperforming Other Medical Stocks This Year?
Bayer Sells Animal Health Division to Elanco: Now What?
by Mitchell Moore
On Tuesday, Bayer (BAYRY) announced the sale of its animal-health division to American competitor Elanco (ELAN), for a net price of $7.6 billion. The deal is expected to close in mid-2020 after regulatory approval.